Emmanuel Antonarakis
@EAntonarakis
Followers
924
Following
177
Media
36
Statuses
172
Professor of Medicine, University of Minnesota, Prostate cancer physician-scientist
Minneapolis, MN
Joined December 2019
RT @neerajaiims: Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in….
0
60
0
Largest retrospective study (N=93) of checkpoint-inhibitor efficacy in pts with dMMR mCRPC. Those with 3-4 modes of dMMR detection (protein IHC loss, gene alteration, MSI-hi, and TMB >20) have greatest survival.
0
15
33
A novel west-African germline founder mutation in HOXB13 (p.X285Kext) increases risk of high-grade prostate cancer but also enhances sensitivity to hormonal therapy. Congrats to PCF-funded Mayuko Kanayama 👏 @neerajaiims @PCFnews @urotoday @EdEsplin
3
22
61
Congrats @chadihcmd for this impactful study. You are a superstar ⭐️.
Just in @CCR_AACR 👉Congrats @chadihcmd @umangtalking & @Huntsman_GU team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 @flatironhealth @FoundationATCG @RyonGraf 👉 need to add PARPi 👉free link: @OncoAlert @urotoday
1
3
12
RT @neerajaiims: Just in @CCR_AACR 👉Congrats @chadihcmd @umangtalking & @Huntsman_GU team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer ….
0
45
0
Congratulations @aliarafaa on developing the first prognostic blood-based PROTEOMIC biomarker for 177Lu-PSMA-617 efficacy, presented at ASCO ‘25. @UMNCancer @UMNews
1
5
33
Congratulations to Cathy Marshall on her two papers (in the same week!) exploring CH in solid tumors. This is an important and emerging field. @CathyHandy @TempusAI
2
9
42
Largest study of BRCA-associated cancers (24,309) shows that somatic tumor landscape is influenced by germline HRR muts: gBRCA1-altered cancers are enriched in somatic TP53 muts; gATM-altered cancers are depleted in TP53 mut. Congrats @aliarafaa @umncancer
1
8
32
Congrats to John Lozada (MD/PhD student) for deeply characterizing DLL3 expression in neuroendocrine cancers across 29 tumor sites. @carisls @UMNCancer @UMNews @mishabeltran
0
4
33
Thank you @neerajaiims for conducting such a masterful interview and for recognizing the importance of this work.
🧬 Groundbreaking insights into #FOXA1 in #ProstateCancer!.Drs. @neerajaiims @huntsmancancer, @EAntonarakis and Justin Hwang, PhD @UMNCancer discuss:.🔹 FOXA1 mutations found in 15% of cases, higher in Asian (25%) & Black (20%) patients.🔹 Opposing clinical outcomes from
0
3
23
Congratulations @CathyHandy and thanks to @mrinalpatnaik for mentoring us.
Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies. @CathyHandy @EAntonarakis #Lutetium #Actinium #CH #PPM1D #TP53 @MayoCancerCare @JohnsHopkins @UMNews.
0
0
2
The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Different FOXA1 classes have different biologic behaviors, clinical outcomes & racial clustering, esp. Class 1B and 2. @UMNcancer @scottdehm
1
16
66
Congrats @aliarafaa for developing a new method for robust plasma exosome proteomics capable of detecting and quantifying >5000 proteins incl. PSMA, B7H3, TROP2 and STEAP1. A new blood-based biomarker is born! @UMNews
2
2
24
Fascinating case report by @laurasenamd on a PCa patient with heterogeneous prostatic lesions, one with MMR deficiency and the other with BRCA2 loss, both of which led to metastatic outgrowths at different time points and selection pressures.
0
10
30
Amphicrine prostate cancer may be a transitional state between prostate adenoCa and small cell/NEPC. Upregulation of FOXA1 and OTX2 may play a role. Congrats to Megan Ludwig for this deep multi-omic analysis. @UMNCancer @umn_dom @DrJustinDrake @aliarafaa
4
10
44
Six genes involved in androgen production/ uptake/ conversion (APUC) distinguish ligand-driven PCa from AR-driven PCa, and have unique clinical outcomes. Congrats to Justin Hwang and his team. @NimaSharifiMD @charlesryanmd @carisls
2
19
59
Huge congrats to @CathyHandy and @BenTeply for this paradigm-breaking study. In BCR prostate cancer, Olaparib shows profound activity (w/out ADT!) in HRRm+ pts, esp. in BRCA2+ pts (100% response rate). @ThePCCTC @hopkinskimmel @umncancer
6
29
85
BRCAaway: Most compelling study suggesting that combined Abi+Olap is better than sequential Abi→Olap or Olap→Abi for BRCA/ATM-altered 1st-line mCRPC. Congrats to Maha Hussain, @ThePCCTC, @neerajaiims, @ArulChinnaiyan, @ZacheryReicher1, @LeonidasPlatan1
2
45
123
Congrats @eamontoye13 and @arafflemd on your 2 recent papers studying BRAF alterations in PCa. Unlike other BRAF-altered cancers, PCa is characterized by Class II muts and activating fusions, including AR-regulated BRAF fusions.
3
16
44
TRIUMPH study: First trial to show that PARP inhibition can work in the absence of ADT (hormone-sparing approach) for men with germline HRR-altered mHSPC, esp. for gBRCA2! Congrats to @MarkowskiGUOnc for leading this paradigm-shifting trial. @CathyHandy
8
28
88